$145.03
0.19% yesterday
Nasdaq, Sep 22, 10:00 pm CET
ISIN
US4576693075
Symbol
INSM

Insmed Incorporated Stock price

$145.03
+13.15 9.97% 1M
+65.65 82.70% 6M
+75.99 110.07% YTD
+73.21 101.94% 1Y
+122.86 554.17% 3Y
+111.83 336.84% 5Y
+120.92 501.53% 10Y
+132.83 1,088.77% 20Y
Nasdaq, Closing price Mon, Sep 22 2025
+0.27 0.19%
ISIN
US4576693075
Symbol
INSM
Industry

Key metrics

Basic
Market capitalization
$30.7b
Enterprise Value
$29.4b
Net debt
positive
Cash
$1.9b
Shares outstanding
211.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
77.0 | 63.9
EV/Sales
73.8 | 61.2
EV/FCF
negative
P/B
24.5
Financial Health
Equity Ratio
14.1%
Return on Equity
-320.2%
ROCE
-42.8%
ROIC
-
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$398.1m | $479.9m
EBITDA
$-922.6m | $-988.9m
EBIT
$-927.7m | $-1.0b
Net Income
$-1.0b | $-1.2b
Free Cash Flow
$-868.6m
Growth (TTM | estimate)
Revenue
21.2% | 32.0%
EBITDA
-44.4% | -26.5%
EBIT
-44.1% | -33.1%
Net Income
-28.9% | -29.3%
Free Cash Flow
-47.1%
Margin (TTM | estimate)
Gross
75.7%
EBITDA
-231.8% | -206.1%
EBIT
-233.0%
Net
-259.8% | -246.2%
Free Cash Flow
-218.2%
More
EPS
$-5.5
FCF per Share
$-4.1
Short interest
5.5%
Employees
1k
Rev per Employee
$290.0k
Show more

Is Insmed Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Insmed Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Insmed Incorporated forecast:

24x Buy
92%
2x Hold
8%

Analyst Opinions

26 Analysts have issued a Insmed Incorporated forecast:

Buy
92%
Hold
8%

Financial data from Insmed Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
398 398
21% 21%
100%
- Direct Costs 97 97
31% 31%
24%
301 301
18% 18%
76%
- Selling and Administrative Expenses 564 564
48% 48%
142%
- Research and Development Expense 660 660
28% 28%
166%
-923 -923
44% 44%
-232%
- Depreciation and Amortization 5.05 5.05
0% 0%
1%
EBIT (Operating Income) EBIT -928 -928
44% 44%
-233%
Net Profit -1,034 -1,034
29% 29%
-260%

In millions USD.

Don't miss a Thing! We will send you all news about Insmed Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insmed Incorporated Stock News

Neutral
PRNewsWire
one day ago
—Data from Phase 2b Study of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Arterial Hypertension to be Presented at Late-Breaking ALERT Session — —New  Analysis from Phase 3 ASPEN Trial Examines Efficacy and Safety of Brensocatib in Japanese Patients with Non-Cystic Fibrosis Bronchiectasis by Reduction of Exacerbation History—  BRIDGEWATER, N.J. , Sept. 22, 2025 /PRNewswire...
Neutral
Seeking Alpha
13 days ago
Insmed Incorporated (NASDAQ:INSM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants William Lewis - President, CEO & Chairman Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst I'm Max Skor, a biotech analyst with Morgan Stanley, and I'm honored to have Will Lewis here, ...
Neutral
Seeking Alpha
18 days ago
Insmed Incorporated (NASDAQ:INSM ) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:00 AM EDT Company Participants Sara Bonstein - Chief Financial Officer Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Presentation Tiago Fauth Equity Analyst All right. Thanks, everyone, for joining us.
More Insmed Incorporated News

Company Profile

Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Will Lewis
Employees 1,271
Founded 1988
Website insmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today